Trillium Therapeutics

About:

Trillium is a biotech company focused on developing therapy treatments for cancer.

Website: http://www.trilliumtherapeutics.com

Twitter/X: Trillium_Tx

Top Investors: New Enterprise Associates, BDC Venture Capital, Frazier Healthcare Partners, Pfizer Breakthrough Growth Initiative

Description:

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Total Funding Amount:

$282M

Headquarters Location:

Toronto, Ontario, Canada

Founded Date:

2004-01-01

Contact Email:

info(AT)trilliumtherapeutics.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2020-09-10

IPO Status:

Public

Industries:

© 2025 bioDAO.ai